article thumbnail

David Liu receives Breakthrough Prize in Life Sciences

Broad Institute

The organization has honored Liu for the development of the gene editing platforms base editing and prime editing, which can correct the vast majority of known disease-causing genetic variations and have already been used in at least 15 clinical trials, with life-saving results.

Science 138
article thumbnail

Statement on the fifth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic

The Pharma Data

The fifth meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (IHR) (2005) regarding the coronavirus disease (COVID-19) took place on Thursday, 29 October 2020 from 12:30 to 16:05 Geneva time (CEST). Proceedings of the meeting. Advice to the WHO Secretariat.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Forging a Path Forward for Substance Abuse Potential Studies With the Cross-Company Abuse Liability Council By Beatrice Setnik, PhD

Alta Sciences

We are the leading organization in conducting substance abuse clinical trials, with principal investigators who collectively bring over 50 years of experience in the field of substance abuse, and with a team of physicians who have extensive expertise in identifying participants for substance abuse studies. Tags Clinical Trials Weight 16

article thumbnail

Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19

The Pharma Data

The clinical trial to evaluate the safety and efficacy of the plasma-derived medicine will have doctors Oriol Mitjà and Bonaventura Clotet as the principal researchers and is expected to begin in early 2021. BARCELONA, Spain , Jan. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P, BARCELONA, Spain , Jan.

article thumbnail

phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia

The Pharma Data

No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The full results of the trial will be submitted for publication in a peer-reviewed journal later this year. About the REMDACTA Trial. The REMDACTA trial is being conducted in collaboration with Gilead Sciences, Inc. About the COVACTA Trial.

Trials 52
article thumbnail

AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial

The Pharma Data

The REVIVAL Phase III pivotal trial is a randomized, double-blind, placebo-controlled, two-arm, parallel-group, multi-center trial to evaluate the efficacy and safety of AM-Pharma’s proprietary human recombinant alkaline phosphatase for the treatment of patients with SA-AKI. Professor Peter Pickkers, M.D., pharma.com. and Chawla L.S.

Trials 52
article thumbnail

Renal Insufficiency May Worsen Multiple Myeloma Outcomes

The Pharma Data

from the University of Kansas City in Kansas, and colleagues conducted a systematic review of all MM randomized clinical trials (RCTs) from 2005 to 2019 to examine reporting of prevalence, eligibility criteria, and outcomes of patients with RI and MM. Ghulam Rehman Mohyuddin, M.D., Data were included for 123 RCTs.